Vaccine-induced human antibodies to PspA augment complement C3 deposition on Streptococcus pneumoniae
- 11 October 2007
- journal article
- Published by Elsevier BV in Microbial Pathogenesis
- Vol. 44 (3), 204-214
- https://doi.org/10.1016/j.micpath.2007.09.007
Abstract
No abstract availableKeywords
This publication has 58 references indexed in Scilit:
- A New Imperative for Global Pneumonia Control: A CommentaryThe Pediatric Infectious Disease Journal, 2007
- Invasive Pneumococcal Disease Caused by Nonvaccine Serotypes Among Alaska Native Children With High Levels of 7-Valent Pneumococcal Conjugate Vaccine CoverageJAMA, 2007
- Relative Roles of Genetic Background and Variation in PspA in the Ability of Antibodies to PspA To Protect against Capsular Type 3 and 4 Strains of Streptococcus pneumoniaeInfection and Immunity, 2003
- Age-dependent preference in human antibody responses toStreptococcus pneumoniaepolypeptide antigensClinical and Experimental Immunology, 2002
- Pneumococcal Surface Protein A of InvasiveStreptococcus pneumoniaeIsolates from Colombian ChildrenEmerging Infectious Diseases, 2001
- Pneumococcal Surface Protein A of InvasiveStreptococcus pneumoniaeIsolates from Colombian ChildrenEmerging Infectious Diseases, 2001
- ComplementNew England Journal of Medicine, 2001
- Truncated Streptococcus pneumoniae PspA Molecules Elicit Cross-Protective Immunity against Pneumococcal Challenge in MiceThe Journal of Infectious Diseases, 1996
- Use of insertional inactivation to facilitate studies of biological properties of pneumococcal surface protein A (PspA).The Journal of Experimental Medicine, 1987
- Monoclonal antibodies against protease-sensitive pneumococcal antigens can protect mice from fatal infection with Streptococcus pneumoniae.The Journal of Experimental Medicine, 1984